Severe COVID-19 Outcomes in Five Latin American Countries in the Postvaccination Era

Author:

Silva Julian Guilherme1ORCID,Spinardi Júlia23,Diaz-Puentes Melissa4,Buitrago Diana4ORCID,García Ida Caterina5,Kyaw Moe H.6ORCID

Affiliation:

1. Evidence Generation Medical Affairs, Pfizer Inc., São Paulo 04717-904, Brazil

2. Vaccines Medical Affairs, Pfizer Inc., São Paulo 04717-904, Brazil

3. Faculdade de Ciências Médicas da Santa Casa de São Paulo, São Paulo 01224-001, Brazil

4. Real World Insights (RWI), IQVIA, Bogotá 110110, Colombia

5. Real World Insights (RWI), IQVIA, Ciudad de México C.P. 03810, Mexico

6. Vaccines Clinical Epidemiologist Emerging Markets, Pfizer Inc., Collegeville, PA 19426-3982, USA

Abstract

We conducted a multicountry retrospective study using data from COVID-19 national surveillance databases to analyze clinical profiles, hospitalization rates, intensive care unit (ICU) admissions, utilization of ventilatory support, and mortality rates in five Latin American countries in the context of COVID-19 vaccination implementation. We analyzed the sociodemographic characteristics, comorbidities, clinical outcomes, and vaccination status of laboratory-confirmed COVID-19 cases from January 2021 to December 2022. We calculated the yearly and quarterly hospitalization rates per 1000 confirmed COVID-19 cases and ICU admissions, use of mechanical ventilators, and mortality rates per 1000 hospitalized cases, with their corresponding 95% confidence interval (CI) of 38,852,831 confirmed COVID-19 cases. Rates of hospitalization, ICU admission, ventilatory support, and death were higher among males than among females (38.2 vs. 32.4, 148.4 vs. 117.7, 282.9 vs. 236.2, and 346.9 vs. 320.1 per 1000, respectively); higher in 2021 than in 2022 (50.7 vs. 19.9, 207.8 vs. 58.2, 441.5 vs. 114.9, and 352.5 vs. 285.2 per 1000, respectively); and in the >50 age group (range: 5.7–18.6, 20.1–71.5, 12.2–67.9, and 353.1–577.4, per 1000) than the <50 age group (range: 2.2–9.3, 5.4–33.2, 41.4–135.8, and 22–243.5 per 1000). Hypertension and diabetes mellitus were the most common comorbidities in Mexico and Colombia. Prevention and treatment strategies for these case profiles could bring benefits from a public health perspective.

Funder

Pfizer

Publisher

MDPI AG

Reference32 articles.

1. World Health Organization (2023, November 15). WHO Coronavirus (COVID-19) Dashboard. Available online: https://data.who.int/dashboards/covid19/cases?n=c.

2. PAHO (2024, January 05). Cumulative Confirmed and Probable COVID-19 Cases Reported by Countries and Territories in the Region of the Americas. Available online: https://ais.paho.org/phip/viz/COVID19Table.asp.

3. COVID-19 in Latin America: A Snapshot in Time and the Road Ahead;LaRotta;Infect. Dis. Ther.,2023

4. Kim, Y.C., and Arturo, R.-S. (2022). Viral-Vectored Vaccines against SARS-CoV-2. Biomedical Innovations to Combat COVID-19, Academic Press.

5. Graña, C., Ghosn, L., Evrenoglou, T., Jarde, A., Minozzi, S., Bergman, H., Buckley, B.S., Probyn, K., Villanueva, G., and Henschke, N. Efficacy and Safety of COVID-19 Vaccines. Cochrane Database Syst. Rev., 2022.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3